News

Neurim wins the battle but not (yet) the war for innovators

03 September 2012

While the EU decision on supplementary protection certificates might be good news for drug companies that find new uses for 'old' active ingredients, it raises more questions than it answers and leaves lingering uncertainty for many other companies.

While the EU decision on supplementary protection certificates might be good news for drug companies that find new uses for 'old' active ingredients, it raises more questions than it answers and leaves lingering uncertainty for many other companies, argue Mike Snodin and Michael Pears.

This article was published in the September issue of Scrip Regulatory Affairs.

View attachment: Download File

People tagged in this article:


Back to all news